AN OPEN LETTER TO THE SCIENTIFIC COMMUNITY ON THE POSSIBLE ROLE OF DYSREGULATED BRADYKININ SIGNALING IN COVID-19 RESPIRATORY COMPLICATIONS

In this Open Letter to the Scientific Community, we propose a model for dysregulated bradykinin signaling in COVID-19 respiratory complications. Based on our model, we suggest the off-label and compassionate use of the FDA-approved bradykinin receptor blocker, icatibant, for patients with unremitting respiratory distress from COVID-19.